CSIMarket
 
Scholar Rock Holding Corp  (SRRK)
Other Ticker:  
 
 
Price: $15.6800 $0.18 1.161%
Day's High: $15.995 Week Perf: -1.13 %
Day's Low: $ 15.33 30 Day Perf: 12.4 %
Volume (M): 656 52 Wk High: $ 21.17
Volume (M$): $ 10,285 52 Wk Avg: $10.06
Open: $15.49 52 Wk Low: $5.56



 Market Capitalization (Millions $) 1,264
 Shares Outstanding (Millions) 81
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -159
 Cash Flow (TTM) (Millions $) -65
 Capital Exp. (TTM) (Millions $) 0

Scholar Rock Holding Corp
Scholar Rock Holding Corp is a clinical-stage biopharmaceutical company that focuses on developing innovative medicines to treat serious diseases in a variety of therapeutic areas. The company's platform is based on targeting the TGF-beta superfamily of proteins, which play a crucial role in regulating cellular processes. Scholar Rock is dedicated to discovering and developing potential therapies that can modulate the TGF-beta superfamily in order to address significant unmet medical needs. The company's pipeline consists of various drug candidates that are undergoing clinical trials for conditions such as fibrosis, immuno-oncology, and musculoskeletal disorders.


   Company Address: 301 Binney Street, 3rd Floor Cambridge 2142 MA
   Company Phone Number: 259 3860   Stock Exchange / Ticker: NASDAQ SRRK
   SRRK is expected to report next financial results on March 06, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stock Transactions

Scholar Rock Empowers New Hires with Inducement Equity Awards Amidst Company Expansion

Published Fri, Feb 16 2024 9:15 PM UTC

Scholar Rock Grants Inducement Equity Awards to New Employees amidst Company Growth
Scholar Rock (NASDAQ: SRRK) has recently announced the granting of inducement equity awards to four newly hired employees, totaling 131,688 shares of its common stock. The awards, which consist of stock options, are a part of the company's efforts to attract and retain top talent as it co...

Management Changes

Scholar Rock's Resilience Shown Through Board Appointments and Financial Transformations

Published Thu, Feb 15 2024 1:00 PM UTC


In a recent announcement, Scholar Rock, a pioneering biopharmaceutical company focused on innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases, revealed the addition of Katie Peng to its Board of Directors and the promotion of Mo Qatanani, Ph.D., as Chief Scientific Officer. These developments have significant im...

Product Service News

Scholar Rock's SRK-439 Shows Weight Loss Management Potential and Anti-PD-1 Resistant Anti-Tumor Activity in Preclinical Studies

Published Tue, Feb 6 2024 1:00 PM UTC

Scholar Rock, a late-stage biopharmaceutical company, has released data from recent preclinical trials, presenting the potential of its promising innovations SRK-439 and SRK-181 in the treatment of cardiometabolic disorders and resistant advanced cancers, respectively.The company's research on SRK-439, showcased its potential benefits in weight loss management through enhanc...

Product Service News

Scholar Rock Unveils Preclinical Data on the Potential Role of SRK-439 in Combatting Obesity

Published Thu, Jan 25 2024 1:00 PM UTC

Cambridge-based late-stage biopharmaceutical company, Scholar Rock, will reportedly present novel preclinical data evaluating its SRK-439 in obesity at the forthcoming Keystone Symposia entitled 'Obesity: Causes and Consequences'. The event is slated to take place from February 4 to 6, 2024, in Vancouver, BC, Canada.Scholar Rock operates within the biopharmaceutical sector w...

Contract

Scholar Rock Receives FDA Clearance to Advance Breakthrough Treatment for Obesity - A Revolutionary Approach to Tackling Metabolic Disorders

Published Tue, Jan 23 2024 1:00 PM UTC

Scholar Rock, a prominent biopharmaceutical company specializing in innovative treatments for various diseases, has recently achieved a significant milestone ?? the FDA clearance of its Investigational New Drug (IND) application for a Phase 2 proof-of-concept trial involving apitegromab. This trial aims to assess the potential of apitegromab as a therapeutic solution for obe...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com